29.6% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Thu Sep 11, 9:36AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 8 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Uptrend Call Working As Chelsea Therapeutics International Stock Rises 29.6% (CHTP)
Comtex SmarTrend(R) - Wed Sep 03, 5:14PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 8 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Chelsea Therapeutics International Has Returned 29.6% Since SmarTrend Recommendation (CHTP)
Comtex SmarTrend(R) - Tue Jul 22, 9:57AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 6 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Chelsea Therapeutics International Shares Up 29.6% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Mon Jul 07, 5:42PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 6 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Lundbeck Completes Acquisition of Chelsea Therapeutics
Business Wire - Tue Jun 24, 9:00AM CDT
H. Lundbeck A/S (Lundbeck) today announced that it has completed its acquisition of Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) (Chelsea) for USD 6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional USD 1.50 per share upon achievement of certain sales milestones, in each case without interest and subject to any required withholding of taxes. As a result of the acquisition, Chelsea became a wholly-owned indirect subsidiary of Lundbeck, and shares of Chelsea common stock will no longer be listed on the NASDAQ Capital Market.
Downgrade Alert for Chelsea Therapeutics International (CHTP)
Comtex SmarTrend(R) - Tue Jun 24, 6:55AM CDT
Chelsea Therapeutics International (NASDAQ:CHTP) was downgraded from Outperform to Neutral at Wedbush today. The stock closed yesterday at $6.52 on volume of 6.1 million shares, above average daily volume of 6.1 million. Chelsea Therapeutics International Ltd. is a biopharmaceutical company developing a pipeline of low toxicity antifolate compounds engineered to have anti-inflammatory and anti-tumor activity. The Company's lead candidate is in development as a metabolically inert treatment alternative to Methotrexate for rheumatoid arthritis, psoriasis, and other disorders.
Shares of CHTP Up 31.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 23, 10:00AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 31.81% as of today's recent price of $6.63.
NORTHERA(TM) Clinical Trial Data Published in Neurology
GlobeNewswire - Thu Jun 19, 3:30PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the publication in Neurology of its pivotal, Phase 3 study 301, a multicenter, multinational, double-blind, randomized, placebo-controlled, parallel-group study of NORTHERA (droxidopa) that details how NORTHERA demonstrated a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH).
Upcoming Conferences, Tentative Meeting Schedules, Analyst Day, Public Offerings, and Data Presentations - Analyst Notes on Incyte, NPS Pharmaceuticals, Arrowhead, Novavax and Chelsea Therapeutics
PR Newswire - Tue Jun 17, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Arrowhead Research Corp. (NASDAQ: ARWR), Novavax, Inc. (NASDAQ: NVAX) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3787-100free.
Uptrend Call Working As Chelsea Therapeutics International Stock Rises 30.0% (CHTP)
Comtex SmarTrend(R) - Mon Jun 16, 9:24AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 30.02% as of today's recent price of $6.54.
Chelsea Therapeutics Presents Efficacy and Safety Data for NORTHERA at International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 12, 6:29AM CDT
-First Presentation of Integrated Data Analyses From Two Pivotal Trials
13.9% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Wed Apr 02, 9:15AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 3 months, Chelsea Therapeutics International has returned 13.91% as of today's recent price of $5.73.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews